SCHEMBL95201

SCHEMBL95201

[CH2]c1ccc(NS(=O)(=O)c2cc(Cl)ccc2OC)cc1

nearest known ligand 0.69

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.69
LMNA P02545 1/20 0.69
HTT P42858 1/20 0.69
TP53 P04637 4/20 0.66
ALPL P05186 9/20 0.62
NPC1 O15118 1/20 0.61
TSHR P16473 1/20 0.61
WDR5 P61964 1/20 0.60
USP2 O75604 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.57
PTPN2 P17706 1/20 0.56
PTPN1 P18031 1/20 0.56
PTPN5 P54829 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7571589 0.86 LMNA (0.73) NPSR1LMNAHTTTP53ALPL
SCHEMBL7578214 0.86 USP2 (0.73) NPSR1LMNAHTTTP53ALPL
SCHEMBL95715 0.84 SMN1; SMN2 (0.71) NPSR1LMNATP53ALPLSMN1; SMN2
SCHEMBL12971600 0.83 USP2 (0.76) NPSR1LMNAHTTALPLWDR5
SCHEMBL7529463 0.82 TP53 (0.80) NPSR1LMNAHTTTP53ALPL
SCHEMBL95927 0.81 ALDH1A1 (0.67) LMNAHTTTP53ALPLTSHR
SCHEMBL22095987 0.81 SMN1; SMN2 (0.78) NPSR1LMNAHTTTP53ALPL
SCHEMBL25754817 0.81 NPSR1 (0.62) NPSR1LMNAHTTTP53ALPL
SCHEMBL95649 0.80 SLC22A12 (0.55) LMNAHTTSMN1; SMN2PTPN2PTPN1
SCHEMBL7594909 0.78 NPC1 (0.89) NPSR1LMNAHTTALPLNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB NPSR1 1479/4885LMNA 3740/4885HTT 4495/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 NPSR1 2023/4885LMNA 4860/4885HTT 4175/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 NPSR1 2023/4885LMNA 4860/4885HTT 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.